Shots:
- Prilenia & Ferrer have entered into a collaboration & license agreement to co-develop & commercialize pridopidine for indications beyond HD in Europe & select markets, with Prilenia retaining rights in major markets incl. North America, Japan, & APAC
- As per the deal, Prilenia will receive ~$90.8M upfront, ~$51.1M in near-term development, regulatory, & commercial milestones, plus additional milestone payments, making an aggregate of ~$568M & is eligible to receive net sales-based tiered double-digit royalties
- Additionally, Prilenia & Ferrer plan to initiate a P-III trial of pridopidine in ALS to confirm P-II (HEALEY ALS) trial results, with CHMP opinion for HD expected in H2’25. Discussions with the FDA are ongoing to determine next steps for HD in the US
Ref: BussinessWire| Image: Prilenia & Ferrer
Related News:- Orion Pharma Collaborates with Criceto for Aporon to Treat OFF Episodes in Parkinson’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information, connect with us at connect@pharmashots.com
